Teruel JL, Lasuncion MA, Tato A, Rivera ME, Aguilera A,
Marcen R, Ortuno J
Lipoprotein reduction in dialysis patients after androgen
therapy
Am Soc Nephrol
J Am Soc Nephrol (abstract)
(Sep) 7:1466 1996
In a prospective controlled (non random) 6 month study, Teruel et al
administered either nandrolone decanoate (200 mg/wk, 14 males) or EPO (2000
u/dialysis SC, 8 females, 4 males). They observed a similar increase in Hb:
7.9 to 10.8 g/dl (androgen) and 7.7 to 10.8 (EPO), p<0.01.
Interestingly, they also observed a 74% decrease in serum Lp(a) from 19.8
to 7.1 mg/dl in the androgen group whereas no change occured in the EPO
group. Serum cholesterol and TG did not change, whereas ApoB increased and
HDL2 decreased. These changes were reversed after stopping treatment for 2
months. There was no correlation between changes in Lpa and Hb.
Comment: The authors conclude in a potential beneficial effect of
androgen treatment on a cardiovascular risk factor generally difficult to
improve.
(Denis Fouque, M.D., University of Lyons, France)
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
Am Soc Nephrol
CRF by problem area :
Anemia/Erythropoietin/Iron
CRF by organ system :
Cardiovascular/Hypertension